At ESTRO 2026, investigators reported that two larger radiotherapy sessions delivered over eight days achieved control for early-stage prostate cancer with a safety and tolerability profile comparable to the conventional five-fraction schedule. The report, presented in Stockholm, centers on reducing treatment burden for patients without adding additional side effects, a factor that could influence how oncologists think about convenience and resource use in radiation oncology.